Home » Stocks » QLGN

Qualigen Therapeutics, Inc. (QLGN)

Stock Price: $3.44 USD 0.09 (2.69%)
Updated December 3, 4:00 PM EST - Market closed
After-hours: $3.41 -0.03 (-0.87%) Dec 3, 7:59 PM

Stock Price Chart

Key Info

Market Cap 79.33M
Revenue (ttm) 1.74M
Net Income (ttm) -28.80M
Shares Out 19.80M
EPS (ttm) -3.03
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 3
Last Price $3.44
Previous Close $3.35
Change ($) 0.09
Change (%) 2.69%
Day's Open 3.35
Day's Range 3.33 - 3.44
Day's Volume 472,167
52-Week Range 0.16 - 7.80

More Stats

Market Cap 79.33M
Enterprise Value 66.36M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 19.80M
Float n/a
EPS (basic) -3.03
EPS (diluted) -3.03
FCF / Share -0.49
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.29M
Short Ratio 2.08
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 45.55
PB Ratio n/a
Revenue 1.74M
Operating Income -9.54M
Net Income -28.80M
Free Cash Flow -9.67M
Net Cash 12.97M
Net Cash / Share 0.56
Gross Margin 8.17%
Operating Margin -547.74%
Profit Margin -1,653.70%
FCF Margin -555.24%
ROA -24.46%
ROE n/a
ROIC 372.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$10.00*
Low
10.0
Current: $3.44
High
10.0
Target: 10.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014
Revenue------
Operating Income-10.84-17.89-7.90-18.45-8.91-2.28
Net Income-10.13-16.87-7.86-18.38-8.79-2.47
Shares Outstanding0.380.210.090.040.01-
Earnings Per Share-26.50-91.50-123.75-510.00-777.50-1,697.50
Operating Cash Flow-14.52-13.33-7.40-15.21-5.72-1.16
Capital Expenditures---0.01-0.01-0.02-
Free Cash Flow-14.52-13.33-7.41-15.22-5.74-1.16
Cash & Equivalents1.7014.8022.637.0515.822.75
Total Debt0.10-----
Net Cash / Debt1.6014.8022.637.0515.822.75
Assets2.8015.3222.837.2416.042.96
Liabilities1.705.932.713.131.3517.46
Book Value1.109.3920.134.1014.68-14.50
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Qualigen Therapeutics, Inc.
Country United States
CEO Andrew Ritter

Stock Information

Ticker Symbol QLGN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: QLGN

Description

Qualigen, a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system; ALAN, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; AS1411 for treating viral-based infectious diseases; RAS-F3, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen, Inc. was founded in 1996 and is based in Carlsbad, California.